Nektar Therapeutics (NKTR) earnings
NKTR earnings moved a median of -1.16% by the close. Quarterly and annual NKTR reports and results, each read against the price at its own news timestamp. Back to the NKTR overview →
25 measured NKTR earnings events.
Where these NKTR earnings landedvs 25 measured NKTR earnings reactions
| Middle 50% of NKTR earnings reactions | -4.31% to +1.65% |
|---|---|
| Median reaction (to close) | -1.16% |
| Measured reactions | 25 |
Point-in-time · zero look-ahead
Half of the 25 NKTR earnings events with a measured close landed between -4.31% and +1.65%; 40% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q NEKTAR THERAPEUTICS For: Jun 30 | SEC filing · Form 10-Q | +1.30% | -1.32% | |
| Nektar Therapeutics Announces Second Quarter 2026 Financial Results | Press release | +1.30% | -1.32% | |
| Form 10-Q NEKTAR THERAPEUTICS For: Mar 31 | SEC filing · Form 10-Q | -1.70% | -2.51% | |
| Nektar Therapeutics Reports First Quarter 2026 Financial Results | Press release | -1.70% | -2.51% | |
| Form 10-K NEKTAR THERAPEUTICS For: Dec 31 | SEC filing · Form 10-K | +0.95% | +0.84% | |
| Form 10-Q NEKTAR THERAPEUTICS For: Sep 30 | SEC filing · Form 10-Q | +2.02% | -0.05% | |
| Nektar Therapeutics Reports Third Quarter 2025 Financial Results | Press release | +2.02% | -0.05% | |
| Form 10-Q NEKTAR THERAPEUTICS For: Jun 30 | SEC filing · Form 10-Q | +3.10% | +2.08% | |
| Nektar Therapeutics Reports Second Quarter 2025 Financial Results | Press release | +3.10% | +2.08% | |
| Form 10-Q NEKTAR THERAPEUTICS For: Mar 31 | SEC filing · Form 10-Q | -4.42% | -5.05% | |
| Nektar Therapeutics Reports First Quarter 2025 Financial Results | Press release | -4.42% | -5.05% | |
| Form 10-K NEKTAR THERAPEUTICS For: Dec 31 | SEC filing · Form 10-K | +1.08% | -1.16% | |
| Form 10-Q NEKTAR THERAPEUTICS For: Sep 30 | SEC filing · Form 10-Q | +1.09% | +1.45% | |
| Nektar Therapeutics Reports Third Quarter 2024 Financial Results | Press release | +1.09% | +1.45% | |
| Nektar to Announce Financial Results for the Third Quarter 2024 on Thursday, November 7, 2024, After Close of U.S.-Based Financial Markets | Press release | +1.24% | +1.65% | |
| Form 10-Q NEKTAR THERAPEUTICS For: Jun 30 | SEC filing · Form 10-Q | +1.29% | -4.31% | |
| Nektar Therapeutics Reports Second Quarter 2024 Financial Results | Press release | +1.29% | -4.31% | |
| Nektar to Announce Financial Results for the Second Quarter 2024 on Thursday, August 8, 2024, After Close of U.S.-Based Financial Markets | Press release | -1.64% | -1.64% | |
| Form 10-Q NEKTAR THERAPEUTICS For: Mar 31 | SEC filing · Form 10-Q | +9.09% | +6.67% | |
| Nektar Therapeutics Reports First Quarter 2024 Financial Results | Press release | +9.09% | +6.67% | |
| Nektar to Announce Financial Results for the First Quarter 2024 on Thursday, May 9, 2024, After Close of U.S.-Based Financial Markets | Press release | -3.74% | -9.77% | |
| Form 10-K NEKTAR THERAPEUTICS For: Dec 31 | SEC filing · Form 10-K | +3.41% | +3.40% | |
| Form 10-Q NEKTAR THERAPEUTICS For: Sep 30 | SEC filing · Form 10-Q | -1.23% | -5.94% | |
| Nektar Therapeutics Reports Third Quarter 2023 Financial Results | Press release | -1.23% | -5.94% | |
| Nektar to Announce Financial Results for the Third Quarter 2023 on Tuesday, November 7, 2023, After Close of U.S.-Based Financial Markets | Press release | -0.19% | +2.99% |
Keep exploring
More NKTR: analyst actions → · SEC filings → · NKTR overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| TROVAGENE (TROV) | 906 | -0.52% | 40% |
| KemPharm, Inc. (KMPH) | 901 | -0.21% | 40% |
| Tandem Diabetes Care, Inc. (TNDM) | 895 | +0.13% | 57% |
| Flexion Therapeutics, Inc. (FLXN) | 891 | 0.00% | 48% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.